Phase 3 Parkinson's Disease Trial, Recruiting NCT07229651 Sponsor: Tanta University Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 3 Parkinson's Disease Trial, Recruiting

NCT07229651
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman aged 50 years or older
  • You have been officially diagnosed with Parkinson's disease
  • You are currently taking a medication called levodopa/carbidopa for your Parkinson's disease

Who may not be able to join:

  • Your Parkinson's-like symptoms are caused by another condition rather than Parkinson's disease itself
  • You are currently taking anti-inflammatory medications (such as ibuprofen or similar drugs)
  • You have been diagnosed with an unusual or atypical form of Parkinson's disease (confirm with trial site)
  • You have previously had brain surgery for Parkinson's disease
  • You are currently pregnant or breastfeeding
  • You have a heart or blood vessel condition (such as heart disease)
  • You have a condition that affects how your blood clots
  • You currently have an active cancer
  • You have an addiction to alcohol or drugs
  • You have a known allergy to the medications being studied in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
10 November 2025
Est. completion
20 November 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

change in The Unified Parkinson's Disease Rating Scale (UPDRS).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov